Current Edition

drug development

Patient Engagement and Real-World Data Drive Innovation in Orphan Disease Drug Development

An estimated one in 10 people are affected by a rare disease, and the cumulative economic burden of rare diseases surpasses that of common conditions …

Continue Reading →
COVID-19 pill

Buffett’s Berkshire exited Merck investment just before COVID pill boost, further trimmed AbbVie and BMS holdings

Warren Buffett’s Berkshire Hathaway doesn’t appear to be the oracle of every market movement, at least not in the case of an investment in Merck …

Continue Reading →
drug development

Overview: Pharmacovigilance and Risk Management

Drug development is an expensive, lengthy, and high-risk business taking 1015 years and is associated with a high attrition rate. Approximately only 1 in 10 …

Continue Reading →
biomarker

Recent Advances and Future Challenges Using Biomarkers in Oncology Precision Medicine

Current and future cancer treatment is expected to be shaped and guided by the use of biomarkers that will guide researchers and physicians at every …

Continue Reading →
clinical trials

Digital Adherence: Modern Solutions to an Age-old Problem

Despite spiralling drug development costs and timelines spawning industry-wide efficiency drives, tackling the multibillion-dollar problem of adherence has remained an untapped opportunity – until now. …

Continue Reading →
city

Seoul tops the list of most clinical trials conducted in a city

Seoul ranks first in the world in number of clinical trials per city. It is meaningful that the city shows a significant gap with Houston …

Continue Reading →